Onconetix annual stock-based compensation
2021
2022
2023
2024
2025
Onconetix Stock-Based Compensation Growth & History (ONCO)
Onconetix's stock-based compensation was $74,267 for fiscal 2025.
View full Onconetix company overviewOnconetix annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $74,267 | −$364,386 | −83.07% |
| 2024 | 2024-12-31 | $438,653 | $108,893 | +33.02% |
| 2023 | 2023-12-31 | $329,760 | −$1.6M | −83.30% |
| 2022 | 2022-12-31 | $2.0M | $1.8M | +1417.25% |
| 2021 | 2021-12-31 | $130,141 | — | — |
Onconetix quarterly stock-based compensation
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $7,359 | −$23,623 | −76.25% |
| Q1 2026 | 2026-03-31 | $22,305 | −$6,951 | −23.76% |
| Q4 2025 | 2025-12-31 | $4,234 | −$336,191 | −98.76% |
| Q3 2025 | 2025-09-30 | $9,795 | −$36,558 | −78.87% |
| Q2 2025 | 2025-06-30 | $30,982 | $31,757 | — |
| Q1 2025 | 2025-03-31 | $29,256 | −$23,394 | −44.43% |
| Q4 2024 | 2024-12-31 | $340,425 | — | — |
| Q3 2024 | 2024-09-30 | $46,353 | −$59,049 | −56.02% |
| Q2 2024 | 2024-06-30 | −$775 | −$273,556 | — |
| Q1 2024 | 2024-03-31 | $52,650 | −$132,928 | −71.63% |
| Q3 2023 | 2023-09-30 | $105,402 | −$224,407 | −68.04% |
| Q2 2023 | 2023-06-30 | $272,781 | −$1.2M | −81.15% |
| Q1 2023 | 2023-03-31 | $185,578 | $166,246 | +859.95% |
| Q4 2022 | 2022-12-31 | $178,298 | $154,110 | +637.13% |
| Q3 2022 | 2022-09-30 | $329,809 | $300,501 | +1025.32% |
| Q2 2022 | 2022-06-30 | $1.4M | $1.4M | +4043.65% |
| Q1 2022 | 2022-03-31 | $19,332 | −$22,389 | −53.66% |
| Q4 2021 | 2021-12-31 | $24,188 | — | — |
| Q3 2021 | 2021-09-30 | $29,308 | — | — |
| Q2 2021 | 2021-06-30 | $34,924 | — | — |
| Q1 2021 | 2021-03-31 | $41,721 | — | — |
Onconetix stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, Onconetix's stock-based compensation decreased from $130,141 to $74,267, a change of −$55,874. The latest reported quarter, Q2 2026, shows $7,359.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Onconetix source filings ↗